• Users Online: 22
  • Print this page
  • Email this page
Year : 2022  |  Volume : 2  |  Issue : 1  |  Page : 5-10

Clinical review on mucopolysaccharidosis and its ocular significance

Department of Ophthalmology, IGMC and RI, Puducherry, India

Correspondence Address:
Dr. A Mary Stephen
Department of Ophthalmology, IGMC and RI, Puducherry
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jocr.jocr_12_22

Rights and Permissions

A condition with deficiency of various enzymes which plays a crucial role in the degradation of glycosaminoglycans (GAG) is termed to be mucopolysaccharidosis (MPS). The disease entity is due to abnormal breakdown and diffuse accumulation of GAG in the various system including brain, eye, muscle, lungs, heart, and gastrointestinal system. The disease spectrum is highly varied from slight phenotypic changes to severe life-threatening illness. Morbidity, especially low visual acuity is due to the involvement of cornea (clouding of the cornea), optic nerve abnormality, and also retinopathy. Marked impairment of physical and intellectual function is common. The diagnosis is mostly clinical and advanced testing including enzyme assay and gene testing is required for typing and pinpoint diagnosis. The treatment options are limited in most cases as enzyme replacement therapy is not widely available and expensive. Bone marrow transplantation has been found to be successful but still a cumbersome option. Visual morbidity can be reduced by performing keratoplasty if corneal clouding is significant and visual prognosis is often guarded.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded227    
    Comments [Add]    

Recommend this journal